But, the clinical success of antibodies conjugated to cytotoxic drugs has been limited compared with that of naked antibodies. So far, only one drug has been approved by the FDA: gemtuzumab ...
The global cytotoxic drugs market is on the cusp of remarkable expansion, with projections indicating a substantial increase in market value to USD 18.3 billion by 2033, up from USD 16.3 billion in ...
Antibody-drug conjugates (ADC) are a class of biological drugs for the treatment of tumours. These complex bioconjugates are composed of an antibody and a cytotoxic small molecule drug (payload), and ...
ADCs consist of three modifiable primary components: the antibody backbone, the cytotoxic payload and the linker that joins the two. The drug linker is typically created as a peptide or ...
ADCs are a group of targeted cancer drugs made from a combination of monoclonal antibodies, which help to target the treatment towards cancerous cells, and a cytotoxic drug, which kills those cells.